Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04891757 · ClinicalTrials.gov registry record · Phase 1
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
A Phase 1 study of Refractory Acute Myeloid Leukemia and Refractory Chronic Myelomonocytic Leukemia, sponsored by Foghorn Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 5
- Study locations
NCT04891757 is a Phase 1 study of Refractory Acute Myeloid Leukemia and Refractory Chronic Myelomonocytic Leukemia that is active but no longer recruiting, run by Foghorn Therapeutics. The registered enrollment target is 144 participants, above the 45-participant average among 63 other Refractory Acute Myeloid Leukemia trials with a reported enrollment target (220% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT04891757, a Phase 1 study of Refractory Acute Myeloid Leukemia and Refractory Chronic Myelomonocytic Leukemia, is active but no longer recruiting, sponsored by Foghorn Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 5
- Study locations
Study Summary
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic malignancies.
Conditions Studied
Interventions
- DRUG Decitabine
- DRUG FHD-286
- DRUG Low Dose Cytarabine
Study Locations (5)
California
- City of Hope National Medical Center - Duarte
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04891757
The ClinicalTrials.gov registry entry for NCT04891757 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 63 other Refractory Acute Myeloid Leukemia trials with a reported enrollment target (220% higher). The listed sponsor is Foghorn Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Refractory Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Decitabine is the first listed.
NCT04891757 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04891757 about?
NCT04891757 is a clinical study titled "FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies". This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic mal...
What is the current status of trial NCT04891757?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2021-06-14. Estimated completion is 2027-06.
What conditions does trial NCT04891757 study?
This clinical trial studies the following conditions: Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Myelodysplastic Syndromes, Relapsed Myelodysplastic Syndromes.
What interventions are being tested in trial NCT04891757?
The interventions under investigation include: Decitabine (DRUG), FHD-286 (DRUG), Low Dose Cytarabine (DRUG).
Who is sponsoring clinical trial NCT04891757?
This trial is sponsored by Foghorn Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04891757 being conducted?
This trial has 5 study locations across California, Massachusetts, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Explore more on PlainTrial
Refractory Acute Myeloid Leukemia
All registered trials for this condition
Refractory Chronic Myelomonocytic Leukemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.